Transfer Pricing for Pharmaceuticals & Life Sciences
We provide transfer pricing consulting for pharmaceutical companies, life sciences groups, API manufacturers, formulation businesses and clinical research organisations operating in India.
Manufacturing, distribution and brand-building in one value chain
Pharma transfer pricing in India centres on three recurring issues: contract manufacturing margins under CPM or TNMM, royalty rates for licensed know-how under CUP, and AMP—advertising, marketing and promotion—spend disputes over marketing-intangible ownership.
Transfer pricing for pharmaceutical companies in India can involve several connected transactions within the same supply chain. An Indian entity may manufacture active pharmaceutical ingredients, produce finished formulations, import products for resale, use technology owned by a foreign group company and incur substantial local marketing expenditure.
Each transaction requires separate functional analysis, but the overall position must remain commercially consistent. Manufacturing margins, distribution returns, royalty payments and promotional activities should collectively reflect the functions performed, assets used and risks controlled by each group entity.
Typical pharmaceutical structure
An Indian group company manufactures APIs or formulations, distributes finished products under a group brand, pays royalty for patented technology or technical know-how and undertakes local promotional activities.
A defensible position requires transaction-specific agreements, financial segmentation and an annual transfer pricing benchmarking analysis .
Where transfer pricing applies in pharma
Pharmaceutical groups frequently have multiple controlled transactions covering manufacturing, research, intellectual property and product distribution.
Contract Manufacturing
Contract manufacturing transfer pricing in pharma commonly involves an Indian plant producing APIs, intermediates or formulations for a foreign group principal. The analysis should identify who controls production, inventory, regulatory, capacity-utilisation and product liability risks.
Distribution and Royalty
An Indian distributor may import finished formulations while also paying for access to a group trademark, product dossier, technology or technical support. The distribution return and royalty payment should be examined together to avoid duplication of remuneration.
AMP and Marketing Intangibles
Significant advertising, medical promotion, physician engagement and product-launch expenditure may attract scrutiny where the brand or trademark is legally owned by a foreign associated enterprise. The analysis should focus on actual conduct, contractual rights and the commercial benefit received by the Indian entity.
Clinical Trials and R&D
Indian entities may conduct clinical research, laboratory testing, regulatory support or development work for a foreign principal. The pricing must reflect technical capabilities, decision-making authority, ownership of results and control over development risks.
API and Formulation Trading
Cross-border purchases and sales of APIs, intermediates and finished formulations may be tested using internal or external price comparisons. Product quality, dosage, volume, market, regulatory status and contractual terms can materially affect comparability.
In-Licensing and Out-Licensing
Pharmaceutical groups may license molecules, patents, formulations, trademarks, dossiers or manufacturing technology into or out of India. The royalty structure should reflect the development stage, territory, exclusivity, commercial potential and responsibilities assumed by the licensee.
How pharmaceutical transactions are benchmarked
Method selection depends on the nature of the transaction, reliability of available comparable data and the functional profile of each party.
CPM and TNMM
The Cost Plus Method or Transactional Net Margin Method may be applied to contract manufacturing arrangements. The analysis may compare gross mark-ups or operating margins earned by independent manufacturers with similar products, functions and risk profiles.
Resale Price Method
RPM may be considered for an Indian distributor purchasing finished pharmaceutical products from a group company and reselling them without substantial value addition. Product registration, marketing intensity and inventory risks affect comparability.
CUP Method
CUP is commonly considered for pharma royalty benchmarking in India, technology licences and product transactions where comparable third-party agreements or reliable internal prices are available.
Profit Split Method
PSM may be relevant where group entities make unique and valuable contributions to integrated R&D, molecule development, co-commercialisation or intellectual-property creation and reliable one-sided comparables are unavailable.
Proactive AMP, royalty and manufacturing-margin defence
We start by mapping the complete pharmaceutical value chain, including research, regulatory approvals, manufacturing, quality control, product registration, inventory management, medical promotion and commercial distribution.
For royalty arrangements, we search for genuinely comparable licensing agreements and evaluate the licensed rights, molecule or technology, development stage, exclusivity, territory, expected commercial benefits and obligations of each party.
For AMP matters, we review whether a separate international transaction is supported by the agreements and actual conduct of the parties. We assess the Indian entity's marketing functions, economic interest, distribution margin and overall remuneration rather than relying only on a mechanical comparison of advertising expenditure.
AMP Functional Analysis
Review marketing functions, contractual arrangements, brand rights and overall remuneration before an audit raises the issue.
Royalty Benchmarking
Support royalty rates using pharmaceutical licence agreements and transaction-specific comparability factors.
Manufacturing Margin Study
Benchmark contract manufacturing returns after documenting production functions, assets and controlled risks.
Litigation Readiness
Prepare evidence, economic analysis and technical submissions for complex pharma transfer pricing disputes.
Our pharma transfer pricing services
We support pharmaceutical and life sciences businesses from transaction planning and annual compliance through assessment and appellate proceedings.
TP Documentation and Form 3CEB
Annual Local File documentation and accountant-report coordination for manufacturing, distribution, royalty, research, service and financing transactions.
AMP Defence Strategy
Functional analysis, agreement review, marketing-expenditure segmentation and audit-ready position papers addressing alleged marketing-intangible transactions.
Royalty Benchmarking
Search and analysis of pharmaceutical licence comparables, including adjustments for territory, exclusivity, development stage and rights granted.
Audit and Litigation Support
Technical submission and representation support before the TPO, DRP, CIT(A) and ITAT for pharmaceutical transfer pricing adjustments.
Learn more about our transfer pricing litigation services .
Pharmaceutical transfer pricing questions
Facing an AMP, royalty or manufacturing-margin question?
Discuss your pharmaceutical transfer pricing position with our specialist team before your next assessment.
Related: Transfer Pricing Benchmarking · Transfer Pricing Litigation Support